National Plan for Epilepsy Act

S.494 was introduced on February 10, 2025, in the 119th Congress by Sen. Schmitt (R-MO) and has 19 cosponsors. It was referred to the Senate HELP Committee. The bill requires HHS to establish a National Plan for Epilepsy and an advisory council, coordinating research and services across federal agencies. Critically, the bill authorizes zero dollars in spending — it is a policy-and-coordination-only bill. An identical companion bill (HR1189) has been introduced in the House but likewise remains in committee. The money trail is straightforward: there is no money. Authorization without appropriation means no new federal grants, contracts, or procurement commitments flow to any private company. The bill's provisions sunset on December 31, 2035, but without any funding mechanism, the plan exists only as a reporting and coordination framework. Structural winners and losers: UCB remains the most directly exposed U.S.-traded pure-play in epilepsy, with Briviact and Vimpat generating significant revenue. However, the bill does nothing to change prescribing patterns, pricing, or patient access. Broader CNS pharma players like Vertex (exondysio? no — VX-548 for pain, not epilepsy), Pfizer, Eli Lilly, and AbbVie have CNS divisions but no direct epilepsy product exposure comparable to UCB. The bill's coordination may eventually streamline research, but that is years out and contingent on future appropriations. Real market data shows UCB (United Community Banks — a bank, NOT the Belgian pharma UCB) is miscoded in the provided data. The ticker in the provided data belongs to United Community Banks (a regional bank), not UCB S.A. (the Belgian pharma), which does not trade on U.S. exchanges as . The Belgian pharma UCB trades OTC as $UCBJY. This creates a significant analytical limitation: the pure-play epilepsy company is not directly captured in the provided market data. Timeline: The bill is in the earliest legislative stage. It must pass committee, pass both chambers in identical form, and be signed by the President. Given no funding and no controversy, passage probability is moderate but distant. Any market impact requires at minimum a separate appropriations bill, which has not been introduced.